Temporal trends in the use of antidiabetic medicines: a nationwide 9-year study in older people living in New Zealand.
BACKGROUND
The global burden of diabetes is increasing worldwide. The aim of the study was to investigate the trends in use of antidiabetic medicines among older New Zealanders between 2005 and 2013, and to perform a separate analysis by age, sex, ethnicity, district health board domicile and socioeconomic deprivation index.


METHODS
The study population included individuals' aged 65 years and older living in New Zealand (NZ) captured in the pharmaceutical collections. Repeated cross-sectional analysis of population-level dispensing data was conducted from 1 January 2005 to 31 December 2013. Linear regression model using a gamma link function was used to estimate prevalence ratios and trends between 2005 and 2013. The main outcome measure was the prevalence of antidiabetic medicines in older New Zealanders.


RESULTS
The prevalence of antidiabetic medicines in older New Zealanders increased by 17.6% between 2005 and 2013. Individuals in the 70-74 age group had the highest utilization of each of the classes of antidiabetic medicines and those aged ⩾85 had the lowest utilization. Among the antidiabetic class of medicines, utilization of sulfonylureas was highest and alpha-glucosidase inhibitors the least. The utilization of thiazolidinediones increased over the study period. In 2013, insulin isophane and insulin glargine were the most common insulin analogues used. Insulin use was high in those aged ⩾85 years across the entire study period. The utilization of metformin increased gradually throughout the study period (by 43.9% in 2013 compared with 2005).


CONCLUSIONS
This population-level study showed an increase in utilization of antidiabetic medicines in older people in NZ from 2005 to 2013; however, the increase does not seem to parallel the proportional increase in prevalence of diabetes for the study period. Improving access to newer antidiabetic medicines in line with emerging evidence should be a consideration for decision makers.
School of Pharmacy, University of Otago, P O Box 56, Dunedin 9054, New Zealand.
Prasad S
PS
Nishtala
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Mohammed Saji
MS
Salahudeen
aged; antidiabetic agents; drug utilization; elderly; hypoglycemic agents; prevalence; trends
Diabetes Obes Metab. 2013 Apr;15(4):335-41
23121373
Can J Clin Pharmacol. 2002 Fall;9(3):123-9
12422249
Curr Med Res Opin. 2007 Mar;23(3):489-94
17355730
Diabetes Care. 2011 May;34(5):1127-32
21421800
JAMA Intern Med. 2013 Jul 22;173(14):1300-6
23753199
Endocrinol Metab (Seoul). 2015 Mar 27;30(1):78-83
25827460
Diabetes Care. 2012 Sep;35(9):1897-901
22699297
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):753-8
24723335
J Am Geriatr Soc. 2011 Dec;59(12):2381-3
22188087
Adv Ther. 2007 Jul-Aug;24(4):803-13
17901029
Aust Fam Physician. 2011 Oct;40(10):811-5
22003487
Diabetes Care. 1998 Sep;21(9):1414-31
9727886
Indian J Endocrinol Metab. 2015 Nov-Dec;19(6):744-52
26693423
Diabetes Care. 2011 Aug;34(8):1749-53
21636795
Dement Geriatr Cogn Dis Extra. 2016 Jan 06;5(3):530-41
26955385
Diabetologia. 2006 Sep;49(9):2024-9
16865360
Scand J Prim Health Care. 2001 Sep;19(3):163-9
11697557
Gerontology. 2015;61(3):195-202
25428287
BMC Endocr Disord. 2012 Aug 16;12:15
22898260
JAMA. 2004 Nov 24;292(20):2495-9
15562129
PLoS One. 2014 Feb 12;9(2):e82880
24533045
Diabetes Ther. 2013 Dec;4(2):239-56
24096685
JAMA Intern Med. 2015 Mar;175(3):356-62
25581565
Lancet. 2005 Oct 8;366(9493):1279-89
16214598
N Engl J Med. 2007 Jun 14;356(24):2457-71
17517853
Diabetes Care. 2006 Sep;29(9):2114-6
16936162
Phys Ther. 2008 Nov;88(11):1254-64
18801858
Health Rep. 2003 May;14(3):35-47
12816014